Found 585 clinical trials
A Study to Evaluate the Safety Tolerability and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease
Parkinson's Disease (PD). The secondary objective of this study is to evaluate the pharmacokinetic (PK) profile of BIIB094.The study is open for PD patients with verified presence or absence of mutations in the
- 807 views
- 18 May, 2022
- 14 locations
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)
Parkinson's Disease (PD) who are on stable symptomatic PD medication.
- 99 views
- 09 May, 2022
- 109 locations
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study: Participants will take 225
- 0 views
- 18 May, 2022
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's
- 0 views
- 03 May, 2022
- 70 locations
Ketamine for the Treatment of Depression in Parkinson's Disease (KET-PD)
The main purpose of this study is to examine the efficacy and safety of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD.
- 6 views
- 12 May, 2022
- 1 location
Use of a Non-Invasive Brainstem Neuromodulation Device to Improve Neurovascular Status in Parkinson's Disease
This study is a single-site, double-blinded, randomized clinical trial designed to elucidate mechanism(s) of action for symptomatic benefits observed in Parkinson's disease (PD)
- 0 views
- 18 May, 2022
- 1 location
Study in Parkinson Disease of Exercise (SPARX3)
primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 months in among persons who have not initiated medication for Parkinson Disease (PD) when they
- 146 views
- 25 Apr, 2022
- 25 locations
Parkinson's Disease
IS YOUR CURRENT PARKINSON’S MEDICATION NOT ENOUGH? Learn about a Parkinson’s Research Study at Wake Research in Raleigh, NC.
- 6 views
- 15 Feb, 2022
- 1 location
Genotypic Influences on Network Progression in Parkinson's Disease
GBA gene are the most common genetic risk factors for Parkinson's, affecting about 10 percent of the more than 6 million people estimated to have the disease. Through prior research
- 39 views
- 01 Feb, 2022
- 1 location
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
Parkinson's disease and cognitive impairment.
- 146 views
- 24 Jan, 2020
- 1 location